<DOC>
	<DOCNO>NCT00469014</DOCNO>
	<brief_summary>The goal clinical research study find best dose clofarabine fludarabine give busulfan follow allogeneic blood stem cell transplant . Researchers study whether combination help control disease , look safety combination . Researchers also want find combine busulfan clofarabine alone combine busulfan fludarabine clofarabine improve treatment , compare previous standard method use busulfan fludarabine alone .</brief_summary>
	<brief_title>Busulfan , Fludarabine , Clofarabine With Allogeneic Stem Cell Transplantation Acute Myeloid Leukemia</brief_title>
	<detailed_description>Busulfan chemotherapy drug kill cancer cell bind DNA ( genetic material cell ) . Clofarabine design interfere growth development cancer cell . Fludarabine design interfere DNA repair enzyme leukemic cell repair damage DNA . This may increase likelihood cell die . These drug give try kill cancerous cell weaken immune system order low risk stem cell transplant rejection . If find eligible take part study , randomly assign ( toss coin ) 1 4 study group . Three ( 3 ) group receive busulfan , fludarabine , clofarabine different dose level . The 4th group receive busulfan clofarabine . As study continue , participant assign use method call adaptive randomization . This method work increase chance assign group best result study far . You know group assign . Participants receive busulfan , fludarabine , and/or clofarabine day 4 dos . You first receive additional low-level `` test '' dose busulfan give vein check blood level change time . This information use decide next dose need reach target blood level busulfan . You total 6 1/2 tablespoon blood drawn time check busulfan blood level follow one busulfan treatment . Up 11 sample blood drawn check blood level busulfan next 11 hour follow test dose first high-dose busulfan treatment . Each sample require 1 teaspoon blood . A heparin lock line place vein low number needle stick need draws . If possible blood level test perform technical scheduling reason , receive standard fix ( unchanging ) dose busulfan . Clofarabine fludarabine ( applicable ) give central venous catheter ( CVC ) 1 hour , day , 4 day . Busulfan also give CVC 3 hour . If go receive transplant HLA-nonidentical unrelated donor , also receive thymoglobulin ( ATG ) 4 hour 3 day transplant weaken immune system reduce risk reject transplant . After transplant , receive tacrolimus , methotrexate , immunosuppressive ( lower immune system ) drug standard manner low risk graft-vs-host disease ( GVHD ) , reaction donor 's immune cell recipient 's body . The allogeneic stem cell ( bone marrow peripheral blood stem cell ) also give CVC . You receive drug G-CSF ( filgrastim ) injection skin day , start 1 week transplant , blood cell level return normal . Patients usually stay hospital 4 week stem cell transplantation . After release hospital , continue monitor outpatient infection transplant-related complication least 100 day transplant . You blood test ( 4 tablespoon blood ) bone marrow aspiration perform 1 , 3 , 6 , 12 month transplant , check disease remission ( come back ) . Your health status follow help local doctor find leukemia MDS come back , well check length survival . This investigational study . All drug use study approve FDA treatment cancer . Busulfan approve use stem cell transplantation . The use drug together stem cell transplant experimental . Up 70 patient take part study . All enrol M. D. Anderson Cancer Center .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Diagnosis 1 ) Acute myeloid leukemia past first remission , first subsequent relapse , induction failure , 2 ) Myelodysplastic syndrome intermediate high risk International Prognostic Scoring System score ( IPSS score ) ( 16 ) , fail previous chemotherapy , 3 ) Chronic Myeloid Leukemia , Philadelphiachromosome positive fail / resistant therapy base Gleevec tyrosine kinase inhibitor . 2 . Patient administer intensive systemic chemotherapeutic drug within 21 day prior trial enrollment ( bone marrow transplant ( BMT ) Day 9 ) . Gleevec , alternative tyrosine kinase inhibitor , nonmyelosuppressive agent , low dose cytarabine , hydroxyurea permit indicated control leukemia . All tyrosine inhibitor nonmyelosuppressive agent terminate least one week prior admission treatment . 3 . No uncontrolled infection . Protocol principal investigator ( PI ) final arbiter uncertainty regard whether previous infection resolve appropriate antibiotic therapy . 4. age &lt; /= 60 5 . A related unrelated donor HLAmatched mismatch 1 HLA , A , B , C , DR DQ locus acceptable ( i.e . least 9/10 match relate unrelated donor , match molecular highresolution technique per current standard BMT program ) . 6 . ZUBROD performance status &lt; 2 7 . Life expectancy severely limited concomitant illness . 8 . Left ventricular ejection fraction &gt; /=45 % No uncontrolled arrhythmias symptomatic cardiac disease . 9 . Forced expiratory volume 1 second ( FEV1 ) , force vital capacity ( FVC ) carbon monoxide diffuse capacity ( DLCO ) &gt; /= 50 % expect corrected hemoglobin . In patient &lt; /= 7 year pulmonary function assess per pediatric BMT routine 10 . Serum creatinine &lt; /= 1.5 mg % . 11 . Serum glutamic pyruvic transaminase ( SGPT ) &lt; /= 200 IU/ml , serum bilirubin alkaline phosphatase within accepted laboratory standard normal limit consider clinically significant . No evidence chronic active hepatitis cirrhosis . If positive hepatitis serology , discus Study Chairman perform liver biopsy pror determine study eligibility . 12 . Female patient pregnant ( negative human chorionic gonadotropin ( hCG ) pregnancy test woman childbearingpotential accordance departmental routine ) . 13 . Patient patient 's legal representative , parent ( ) guardian able sign inform consent . 1 . Effusion ascites estimate &gt; 1L prior drainage . 2 . HIVpositive . 3 . Hepatitis C HBsAg positive 4 . Prior stem cell transplant myeloablative conditioning program ( busulfanbased use total dose &gt; /= 12 mg/kg give mouth &gt; /= 10 mg/kg IV , totalbody irradiationbased program . 5 . Active prior Central Nervous System ( CNS ) leukemia 6 . Biphenotypic acute leukemia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludara</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>ASCT</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Imatinib Mesylate</keyword>
</DOC>